Duration (from RSS): 00:13:48
What happens when one autoimmune diagnosis turns into questions about another?
In this episode, Noah and Eloise take a deep dive into the My Adrenal Life article “Schmidt Syndrome, Prediabetes, and Metabolic Risk.” Together, they unpack a topic that can sound overwhelming at first: why autoimmune conditions sometimes cluster together, what Schmidt syndrome – also called Autoimmune Polyglandular Syndrome Type 2 (APS-2) actually means, and why hearing the words “metabolic risk” does not automatically mean the worst.
For people living with autoimmune Addison’s disease, it can be deeply unsettling to learn that the thyroid or pancreas may also need monitoring over time. This episode explains that connection in a clear, grounded way. Rather than framing it as a domino collapse, Noah and Eloise show that APS-2 reflects a shared autoimmune tendency, not a sign that the body is suddenly unraveling all at once.
The conversation breaks down the classic APS-2 pattern: Addison’s disease plus autoimmune thyroid disease and/or Type 1 diabetes. From there, the episode tackles one of the biggest sources of confusion in this space: the difference between autoimmune Type 1 diabetes risk and prediabetes or insulin resistance.
That distinction matters.
Jake and Eloise explain that Type 1 diabetes in APS-2 is autoimmune, meaning the immune system attacks the insulin-producing cells of the pancreas. By contrast, prediabetes and metabolic risk are usually tied to insulin resistance, where the body is still making insulin but not using it as effectively. In adrenal insufficiency, steroid treatment itself can play a role in that picture because cortisol and glucocorticoid medications naturally affect blood sugar handling.
The episode explores how replacement steroids can create imperfect peaks and valleys, and why that may sometimes contribute to rising glucose levels over time without meaning that autoimmune diabetes is developing. This is an important reassurance for listeners who may have seen an A1C drift upward and immediately feared a new autoimmune diagnosis.
Noah and Eloise also discuss why monitoring is preventive, not predictive. Checking thyroid labs, glucose markers, or diabetes antibodies does not mean something terrible is expected. It means doctors are watching known patterns so that, if something changes, it can be caught early and managed well.
Another key part of the conversation focuses on the interaction between thyroid treatment and adrenal insufficiency. The episode explains why untreated adrenal insufficiency needs to be stabilized before thyroid hormone is started or increased, and why that sequencing matters for safety.
Most importantly, this episode offers emotional clarity. Collecting diagnoses can feel frightening and deeply personal. It can make the body feel unsafe or unpredictable. But understanding APS-2 and metabolic risk through a medical lens can replace spiraling fear with a clearer map of what is actually happening and what is simply being monitored.
If you have ever heard terms like Schmidt syndrome, APS-2, prediabetes, or metabolic risk and felt your mind jump straight to catastrophe, this conversation helps separate what is possible, what is common, and what is manageable.
Visit us at www.MyAdrenalLife.com and our Facebook Group